JP2019196370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019196370A5 JP2019196370A5 JP2019124501A JP2019124501A JP2019196370A5 JP 2019196370 A5 JP2019196370 A5 JP 2019196370A5 JP 2019124501 A JP2019124501 A JP 2019124501A JP 2019124501 A JP2019124501 A JP 2019124501A JP 2019196370 A5 JP2019196370 A5 JP 2019196370A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- use according
- effective amount
- therapeutically effective
- ranges
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 108050003475 Neuregulin Proteins 0.000 claims 8
- 102000014413 Neuregulin Human genes 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108050002150 EGF-like domains Proteins 0.000 claims 1
- 102000012545 EGF-like domains Human genes 0.000 claims 1
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000010005 growth-factor like effect Effects 0.000 claims 1
- 102000055650 human NRG1 Human genes 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021179961A JP2022023208A (ja) | 2008-07-17 | 2021-11-04 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13517108P | 2008-07-17 | 2008-07-17 | |
| US61/135,171 | 2008-07-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017150365A Division JP2017200949A (ja) | 2008-07-17 | 2017-08-03 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179961A Division JP2022023208A (ja) | 2008-07-17 | 2021-11-04 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019196370A JP2019196370A (ja) | 2019-11-14 |
| JP2019196370A5 true JP2019196370A5 (enExample) | 2020-02-20 |
Family
ID=42005671
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518734A Expired - Fee Related JP5797112B2 (ja) | 2008-07-17 | 2009-07-17 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2015013248A Expired - Fee Related JP6189879B2 (ja) | 2008-07-17 | 2015-01-27 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2017150365A Pending JP2017200949A (ja) | 2008-07-17 | 2017-08-03 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2019124501A Pending JP2019196370A (ja) | 2008-07-17 | 2019-07-03 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2021179961A Pending JP2022023208A (ja) | 2008-07-17 | 2021-11-04 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518734A Expired - Fee Related JP5797112B2 (ja) | 2008-07-17 | 2009-07-17 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2015013248A Expired - Fee Related JP6189879B2 (ja) | 2008-07-17 | 2015-01-27 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2017150365A Pending JP2017200949A (ja) | 2008-07-17 | 2017-08-03 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179961A Pending JP2022023208A (ja) | 2008-07-17 | 2021-11-04 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20110166068A1 (enExample) |
| EP (3) | EP3632459A1 (enExample) |
| JP (5) | JP5797112B2 (enExample) |
| CN (3) | CN104623633A (enExample) |
| AU (3) | AU2009292216B2 (enExample) |
| BR (1) | BRPI0916442A2 (enExample) |
| CA (1) | CA2731113A1 (enExample) |
| DK (2) | DK2320933T3 (enExample) |
| ES (2) | ES2763184T3 (enExample) |
| MX (2) | MX2011000696A (enExample) |
| PL (2) | PL2320933T3 (enExample) |
| RU (4) | RU2536938C2 (enExample) |
| WO (1) | WO2010030317A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3632459A1 (en) * | 2008-07-17 | 2020-04-08 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure |
| EP3777878A1 (en) | 2008-08-15 | 2021-02-17 | Acorda Therapeutics, Inc. | Compositions and methods for treatment during non-acute periods following cns neurological injury |
| EP2808339B1 (en) | 2008-11-28 | 2017-02-15 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin peptides and their use |
| PL2488194T3 (pl) | 2009-10-14 | 2016-11-30 | Zastosowanie neureguliny do leczenia uszkodzenia nerwu jamistego | |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| EP2830645B1 (en) * | 2012-03-30 | 2017-08-30 | Acorda Therapeutics, Inc. | Neuregulin for use in treating peripheral nerve injury |
| AU2014225534A1 (en) * | 2013-03-06 | 2015-09-24 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure |
| BR112015029293A2 (pt) | 2013-05-22 | 2018-04-24 | Zensun Shanghai Science & Tech Ltd | método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| CN105561298A (zh) * | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| US20180296642A1 (en) | 2015-09-25 | 2018-10-18 | Douglas B. Sawyer | Methods for treating cardiac injury |
| CN108778315A (zh) * | 2016-04-19 | 2018-11-09 | 莱布尼茨研究所-针对老化研究(弗里茨利普曼研究所) | 用于治疗和/或预防神经系统肿瘤的神经调节素 |
| CN110835368A (zh) * | 2018-08-15 | 2020-02-25 | 上海泽生科技开发股份有限公司 | 神经调节蛋白多肽片段及其用途 |
| AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| KR20220066116A (ko) * | 2019-09-16 | 2022-05-23 | 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 | 재조합 인간 뉴레귤린 유도체 및 그의 용도 |
| US20250241989A1 (en) * | 2021-10-22 | 2025-07-31 | The Research Institute At Nationwide Children's Hospital | Neuregulin for Protection Against Respiratory Viral Infection and Post-Viral Disease |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US7115554B1 (en) * | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US6087323A (en) | 1992-04-03 | 2000-07-11 | Cambridge Neuroscience, Inc. | Use of neuregulins as modulators of cellular communication |
| US7037888B1 (en) | 1992-04-03 | 2006-05-02 | Acorda Therapeutics, Inc. | Methods for treating muscle diseases and disorders |
| US5811098A (en) * | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| US6136558A (en) * | 1997-02-10 | 2000-10-24 | Genentech, Inc. | Heregulin variants |
| US6051401A (en) | 1998-07-28 | 2000-04-18 | Bayer Corporation | Methods and constructs for protein expression |
| HK1040363B (en) | 1998-09-25 | 2007-01-26 | Cubist Pharmaceuticals Llc | Use of daptomycin |
| AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| CN1138785C (zh) * | 1999-06-04 | 2004-02-18 | 周明东 | 生长因子神经调节蛋白及其类似物的新应用 |
| AU1916301A (en) | 1999-11-12 | 2001-06-06 | Children's Medical Center Corporation | Methods for administration of therapeutic agents on an antiangiogenic schedule |
| EP2357004B1 (en) | 2000-05-23 | 2016-10-12 | CeNeS Pharmaceuticals, Inc. | NRG-2 nucleic acid molecules, polypeptides and diagnostic and therapeutical methods |
| CU23157A1 (es) * | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
| AU2003210549A1 (en) | 2002-01-18 | 2003-09-02 | Chiron Corporation | Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
| WO2003099320A1 (en) * | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| US20070032557A1 (en) * | 2005-02-18 | 2007-02-08 | Matti Kivikko | Method for administering levosimendan |
| US20080279865A1 (en) | 2005-03-23 | 2008-11-13 | Pfizer, Inc., Pfizer Products, Inc. | Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy |
| CA2658326C (en) | 2005-09-02 | 2013-04-23 | Morehouse School Of Medicine | Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue |
| US20070213264A1 (en) * | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| US20070190127A1 (en) | 2005-12-30 | 2007-08-16 | Mingdong Zhou | Extended release of neuregulin for improved cardiac function |
| BRPI0908271A2 (pt) | 2008-02-29 | 2017-06-13 | Acorda Therapeutics Inc | método para alcançar níveis plasmáticos desejados de fator de crescimento glial |
| EP3632459A1 (en) * | 2008-07-17 | 2020-04-08 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure |
| PL2488194T3 (pl) | 2009-10-14 | 2016-11-30 | Zastosowanie neureguliny do leczenia uszkodzenia nerwu jamistego | |
| EP2603221A4 (en) | 2010-08-13 | 2014-02-26 | Univ Georgetown | GGF2 AND METHOD FOR ITS APPLICATION |
| EP2830645B1 (en) | 2012-03-30 | 2017-08-30 | Acorda Therapeutics, Inc. | Neuregulin for use in treating peripheral nerve injury |
-
2009
- 2009-07-17 EP EP19197381.7A patent/EP3632459A1/en not_active Withdrawn
- 2009-07-17 US US13/055,397 patent/US20110166068A1/en not_active Abandoned
- 2009-07-17 CN CN201510010273.9A patent/CN104623633A/zh active Pending
- 2009-07-17 MX MX2011000696A patent/MX2011000696A/es active IP Right Grant
- 2009-07-17 PL PL09813336T patent/PL2320933T3/pl unknown
- 2009-07-17 CN CN201710109733.2A patent/CN107019794B/zh not_active Expired - Fee Related
- 2009-07-17 PL PL17209369T patent/PL3338791T3/pl unknown
- 2009-07-17 ES ES17209369T patent/ES2763184T3/es active Active
- 2009-07-17 CN CN2009801360798A patent/CN102159236A/zh active Pending
- 2009-07-17 DK DK09813336.6T patent/DK2320933T3/en active
- 2009-07-17 AU AU2009292216A patent/AU2009292216B2/en not_active Ceased
- 2009-07-17 EP EP09813336.6A patent/EP2320933B1/en not_active Not-in-force
- 2009-07-17 DK DK17209369.2T patent/DK3338791T3/da active
- 2009-07-17 MX MX2015001826A patent/MX384378B/es unknown
- 2009-07-17 ES ES09813336.6T patent/ES2664394T3/es active Active
- 2009-07-17 CA CA2731113A patent/CA2731113A1/en not_active Abandoned
- 2009-07-17 EP EP17209369.2A patent/EP3338791B1/en active Active
- 2009-07-17 BR BRPI0916442-1A patent/BRPI0916442A2/pt not_active IP Right Cessation
- 2009-07-17 JP JP2011518734A patent/JP5797112B2/ja not_active Expired - Fee Related
- 2009-07-17 RU RU2011105821/10A patent/RU2536938C2/ru active
- 2009-07-17 WO PCT/US2009/004130 patent/WO2010030317A2/en not_active Ceased
-
2013
- 2013-05-29 US US13/904,654 patent/US9198951B2/en active Active
-
2014
- 2014-10-14 RU RU2014141514A patent/RU2698090C2/ru active
-
2015
- 2015-01-27 JP JP2015013248A patent/JP6189879B2/ja not_active Expired - Fee Related
- 2015-05-27 AU AU2015202877A patent/AU2015202877B2/en not_active Ceased
- 2015-10-30 US US14/928,124 patent/US9956266B2/en active Active
-
2017
- 2017-05-26 AU AU2017203528A patent/AU2017203528A1/en not_active Abandoned
- 2017-08-03 JP JP2017150365A patent/JP2017200949A/ja active Pending
-
2018
- 2018-03-29 US US15/940,250 patent/US20180280477A1/en not_active Abandoned
-
2019
- 2019-07-03 JP JP2019124501A patent/JP2019196370A/ja active Pending
- 2019-08-12 RU RU2019125376A patent/RU2719199C1/ru active
- 2019-09-09 US US16/564,739 patent/US11235031B2/en active Active
-
2020
- 2020-03-18 RU RU2020111236A patent/RU2020111236A/ru unknown
-
2021
- 2021-11-04 JP JP2021179961A patent/JP2022023208A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019196370A5 (enExample) | ||
| RU2020111236A (ru) | Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности | |
| JP2016516016A5 (enExample) | ||
| JP2022031772A5 (enExample) | ||
| JP2015187125A5 (enExample) | ||
| JP2016514132A5 (enExample) | ||
| JP2012067116A5 (enExample) | ||
| US20080213288A1 (en) | Combined Use Of A Modulator Of CD3 And A GLP-1 Compound | |
| JP2016074740A5 (enExample) | ||
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2013533858A5 (enExample) | ||
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| JP2011507860A5 (enExample) | ||
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| US20250177364A1 (en) | Combination therapies for breast cancer | |
| JP2014500278A5 (enExample) | ||
| JP2005506345A5 (enExample) | ||
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| RU2009118962A (ru) | Применение антагонистов il-1 для лечения подагры и псевдоподагры | |
| JP2014504601A5 (enExample) | ||
| JP2022035920A5 (enExample) | ||
| EP1450850B1 (en) | Method of administering a thymosin alpha 1 peptide | |
| JP2005529152A5 (enExample) |